Table 2.
Current cytokine-targeting treatment for psoriatic arthritis.
| b/tsDMARDs | Target | Dose and Administration Route | FDA or EMA Approval |
|---|---|---|---|
| Etanercept | TNF-α | 50 mg weekly, SC | FDA, EMA |
| Infliximab | TNF-α | 5 mg/kg at weeks 0, 2, and 6; every 8 weeks thereafter, IV | FDA, EMA |
| Adalimumab | TNF-α | 40 mg every 2 weeks, SC | FDA, EMA |
| Golimumab | TNF-α | 50 mg weekly, SC | FDA, EMA |
| Certolizumab pegol | TNF-α | 200 mg every 2 weeks or 400 mg every 4 weeks, SC | FDA, EMA |
| Ustekinumab | p40 subunit of IL-12 and IL-23 | (BW < 100 kg) 45 mg/kg at weeks 0, 4, and 12; every 12 weeks thereafter, SC (BW > 100 kg) 90 mg/kg at weeks 0, 4, and 12; every 12 weeks thereafter, SC |
FDA, EMA |
| Guselkumab | p19 subunit of IL-23 | 100 mg at weeks 0 and 4; every 8 weeks thereafter, SC | FDA, EMA |
| Risankizumab | p19 subunit of IL-23 | 150 mg at weeks 0 and 4; every 12 weeks thereafter, SC | FDA, EMA |
| Tildrakizumab | p19 subunit of IL-23 | 100 mg at weeks 0 and 4; every 12 weeks thereafter, SC | - |
| Secukinumab | IL-17A | 150 mg weekly for 4 weeks; monthly thereafter, SC | FDA, EMA |
| Ixekizumab | IL-17A | 160 mg at weeks 0 and 80 mg at weeks 2, 4, 6, 8, 10, and 12; 80 mg every 4 weeks thereafter, SC | FDA, EMA |
| Bimekizumab | IL-17A/F | 320 mg every 4 weeks for 16 weeks, every 8 weeks thereafter, SC | EMA |
| Brodalumab | IL-17 receptor | 210 mg at weeks 0, 1, and 2; every 2 weeks thereafter, SC | - |
| Tofacitinib | JAK1/3 | 5 mg twice daily, orally | FDA, EMA |
| Upadacitinib | JAK1 | 15 mg once daily, orally | FDA, EMA |
| Filgotinib | JAK1 | 200 mg once daily, orally | - |
| Deucravacitinib | TYK2 | 6 mg once daily, orally | - |
| Brepocitinib | JAK1/TYK2 | 30 mg or 60 mg once daily, orally | - |
b/tsDMARDs, biological/targeted synthetic disease-modifying anti-rheumatic drugs; EMA, the European Medicines Agency; FDA, the U.S Food and Drug Administration; IV, intravenously; SC, subcutaneously.